^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis
Published date:
06/05/2023
Excerpt:
CONTRADICTING EVIDENCE: A multicentre retrospective analysis was conducted including KRASG12C-mutated mCRC patients treated with first-line FOLFIRI or FOLFOX +/- bevacizumab….Only KRASG12C-mutated patients treated between 2009 and 2021 with either FOLFIRI +/− bevacizumab or FOLFOX +/− bevacizumab were selected....In the unmatched population, objective response rate (ORR) and median (m) progression-free and overall survival (mPFS and mOS) were comparable between the treatment arms. However, a late (>12 months) PFS advantage was observed with irinotecan (HR 0.62, p = 0.02).
Secondary therapy:
FOLFIRI
DOI:
10.3390/cancers15113064
Source:
Title:
369P - Irinotecan is superior to oxaliplatin in KRAS-G12C-mutated (K-G12C-m) colorectal cancer (CRC) and should be preferred in combination strategies with K-G12C inhibitors. A multicenter propensity score-matched (PSM) retrospective analysis
Published date:
09/05/2022
Excerpt:
CONTRADICTING EVIDENCE: In K-G12C-m pts a statistically significant benefit in PFS was demonstrated for FOLFIRI+/-bev vs FOLFOX+/-bev: HR 0.52 (95%CI 0.28-0.98), p 0.04….Irinotecan (i.e. FOLFIRI+/-bev) was significantly superior to oxaliplatin (i.e. FOLFOX+/-bev) in K-G12C-m CRC pts, with a subset of pts (32%) achieving a long-lasting (> 2 yrs) PFS.
Secondary therapy:
FOLFIRI
Source:
Title:
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
Published date:
09/30/2021
Excerpt:
In our cohort of patients, it was observed that KRAS G12C mutations are associated with worse response rates compared to other KRAS variants when treated with standard chemotherapy doublet + Bevacizumab.
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.3389/fonc.2021.736104
Source:
Title:
Retrospective comparative analysis of K-ras G12C vs other K-ras mutations in metastatic colorectal cancer patients treated with first-line chemotherapy doublet + bevacizumab
Published date:
07/04/2021
Excerpt:
K-ras G12C mutations are associated with worse response rates compared to other K-ras isoforms when treated with standard chemotherapy doublet+bevacizumab.
Secondary therapy:
Chemotherapy
DOI:
10.1016/j.annonc.2021.05.023
